In October 2024, WHO and partners, in collaboration with Member States, activated the Global Health Emergency Corps (GHEC) for the first time to provide support to countries facing mpox outbreaks. GHEC is a grouping of professionals with the objective of strengthening the response to health emergencies, and a collaboration platform for countries and health emergency networks. It supports countries on their health emergency workforce, the surge deployment of experts and the networking of technical leaders. GHEC was established by WHO in 2023 after the response to the COVID-19 pandemic revealed the need to streamline efforts of existing networks to ensure better-coordinated support to countries. “WHO and partners are supporting the government of the Democratic Republic of the Congo and other countries to implement an integrated approach to case detection, contact tracing, targeted vaccination, clinical and home care, infection prevention and control, community engagement and mobilization, and specialized logistical support,” said Dr Mike Ryan, Executive Director of WHO’s Health Emergencies Programme. “The GHEC enhances the ability of the many effective responders at national and regional levels to collaborate and ensure the success on the ground in interrupting transmission and reducing suffering.” The first activation of this new support mechanism follows the declaration of mpox as a public health emergency of international concern by WHO Director-General Dr Tedros Adhanom Ghebreyesus on 14 August 2024. Eighteen African countries have reported mpox cases this year, and the rapid spread of clade 1b mpox to at least two other regions has raised concerns about further spread. In collaboration with the International Association of National Public Health Institutes, GHEC is assessing the emergency workforce capacities in 8 countries affected by the mpox outbreak, including the Democratic Republic of the Congo and Burundi, the two most affected countries. The assessment has so far identified 22 areas that need strengthening, including epidemiology and surveillance, laboratory capacities, infection prevention and control, risk communication and community engagement. In the Democratic Republic of the Congo, the Health Cluster partners have joined in strengthening the coordination set up by the Ministry of Health under the leadership of the public health emergency operations centre. As of 17 October, WHO has managed the deployment of 56 experts to the affected countries. This includes WHO staff as well as experts mobilized through the Global Outbreak Alert and Response Network (GOARN) and the African Volunteers Health Corps (AVoHC-SURGE). The AVoHC-SURGE responders, coordinated by WHO’s Regional Office for Africa and the Africa Centres for Disease Control and Prevention, are a growing cohort of professionals with diverse skillsets that can be deployed in the region. “By mobilizing trained professionals from within the continent, we ensure that responses are not only timely but also contextually relevant,” said Dr Abdou Salam Gueye, Regional Emergency Director for the WHO Regional Office for Africa. “The dedication and expertise of these responders are essential in saving lives and building resilient health systems capable of withstanding future threats.” Additionally, GOARN is leading the efforts to map the support provided by partners on a bilateral basis to affected countries and the regional coordination structure. This includes the provision of experts, supplies, financial support, capacity strengthening and other activities.  As part of the GHEC activation, on 22 October, technical leaders from affected countries and leaders from other countries, including those who have experienced previous mpox outbreaks, convened to discuss the most effective control measures, share best practices and coordinate their efforts to halt the outbreak.   Note to editors: GHEC was established by WHO in 2023 in response to the gaps and challenges identified during the COVID-19 response. It supports countries experiencing public health emergencies through three key pillars: Emergency workforce assessment: GHEC conducts assessments of emergency workforce capacities in affected countries to identify gaps and challenges hindering an effective response. Rapid deployment of surge capacities: Countries can request support from various pools of experts with specific skill sets tailored to the identified needs. These experts can be rapidly deployed to affected countries to support the emergency response. Leadership network: Countries nominate representatives to connect with other leaders to share best practices and coordinate the response. Leaders include representatives from national public health agencies, national emergency operation centres or other disease experts.

The World Health Organization (WHO) today published a new report on tuberculosis revealing that approximately 8.2 million people were newly diagnosed with TB in 2023 – the highest number recorded since WHO began global TB monitoring in 1995. This represents a notable increase from 7.5 million reported in 2022, placing TB again as the leading infectious disease killer in 2023, surpassing COVID-19. WHO’s Global Tuberculosis Report 2024 highlights mixed progress in the global fight against TB, with persistent challenges such as significant underfunding. While the number of TB-related deaths decreased from 1.32 million in 2022 to 1.25 million in 2023, the total number of people falling ill with TB rose slightly to an estimated 10.8 million in 2023. With the disease disproportionately affecting people in 30 high-burden countries, India (26%), Indonesia (10%), China (6.8%), the Philippines (6.8%) and Pakistan (6.3%) together accounted for 56% of the global TB burden. According to the report, 55% of people who developed TB were men, 33% were women and 12% were children and young adolescents. “The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it and treat it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “WHO urges all countries to make good on the concrete commitments they have made to expand the use of those tools, and to end TB.” In 2023, the gap between the estimated number of new TB cases and those reported narrowed to about 2.7 million, down from COVID-19 pandemic levels of around 4 million in 2020 and 2021. This follows substantial national and global efforts to recover from COVID-related disruptions to TB services. The coverage of TB preventive treatment has been sustained for people living with HIV and continues to improve for household contacts of people diagnosed with TB.   However, multidrug-resistant TB remains a public health crisis. Treatment success rates for multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) have now reached 68%. But, of the 400 000 people estimated to have developed MDR/RR-TB, only 44% were diagnosed and treated in 2023. Funding gaps and challenges Global funding for TB prevention and care decreased further in 2023 and remains far below target. Low- and middle-income countries (LMICs), which bear 98% of the TB burden, faced significant funding shortages. Only US$ 5.7 billion of the US$ 22 billion annual funding target was available in 2023, equivalent to only 26% of the global target. The total amount of international donor funding in LMICs has remained at around US$1.1 – 1.2 billion per year for several years. The United States government remains the largest bilateral donor for TB. The While Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) is the top contribution to international funder of the TB response, especially in LMICs. is important, it remains However, resources remain insufficient to cover essential TB service needs. The report emphasizes that sustained financial investment is crucial for the success of TB prevention, diagnosis, and treatment efforts. Globally, TB research remains severely underfunded with only one-fifth of the US$ 5 billion annual target reached in 2022. This impedes the development of new TB diagnostics, drugs, and vaccines. WHO continues leading efforts to advance the TB vaccine agenda, including with the support of the TB Vaccine Accelerator Council launched by the WHO Director-General. Complex drivers of the epidemic For the first time, the report provides estimates on the percentage of TB-affected households that face catastrophic costs (exceeding 20% of annual household income) to access TB diagnosis and treatment in all LMICs. These indicate that half of TB-affected households face such catastrophic costs.   A significant number of new TB cases are driven by 5 major risk factors: undernutrition, HIV infection, alcohol use disorders, smoking (especially among men), and diabetes. Tackling these issues, along with critical determinants like poverty and GDP per capita, requires coordinated multisectoral action. “We are confronted with a multitude of formidable challenges: funding shortfalls and catastrophic financial burden on those affected, climate change, conflict, migration and displacement, pandemics, and drug-resistant tuberculosis, a significant driver of antimicrobial resistance,” said Dr Tereza Kasaeva, Director of WHO’s Global Tuberculosis Programme. “It is imperative that we unite across all sectors and stakeholders, to confront these pressing issues and ramp up our efforts.” Global milestones and targets for reducing the TB disease burden are off-track, and considerable progress is needed to reach other targets set for 2027 ahead of the second UN High-Level Meeting. WHO calls on governments, global partners, and donors to urgently translate the commitments made during the 2023 UN High-Level Meeting on TB into tangible actions. Increased funding for research, particularly for new TB vaccines, is essential to accelerate progress and achieve the global targets set for 2027. Note to editors On 31 October 2024, a correction was made to this news release as noted below. The sentence in the original news release read: The total amount of international donor funding in LMICs has remained at around US$ 1.1–1.2 billion per year for several years. The United States government remains the largest bilateral donor for TB. While the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) contribution to international funding of the TB response, especially in LMICs, is important, it remains insufficient to cover essential TB service needs.  This was changed to: The total amount of international donor funding in LMICs has remained at around US$1.1--1.2 billion per year for several years. The United States government remains the largest bilateral donor for TB. The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) is the top international funder of the TB response especially in LMICs however resources remain insufficient to cover essential TB service needs.